STARTUP PROFILE

MaxWell Biosystems

COUNTRY
Switzerland
FOUNDED
2016
CATEGORY
Tools and Infrastructure
Delivering high-density microelectrode array platforms that record and stimulate neural cells in vitro, accelerating neuroscience and drug discovery.
Visit website →
Neurofounders Insights
$   Funding   -
Series A
MODALITY
MEA
FORM FACTOR
Other
INTERFACE DEPTH
Ex vivo
INDICATION
Research
TARGET USER
Mixed
REGULATORY STAGE
Research only
MaxWell Biosystems is a direct peer to 3Brain in the high-density MEA market, supplying ex vivo electrophysiology tools for neuroscience and drug discovery. Its differentiation lies in cell-level recording and stimulation performance, making it infrastructure for pharma and research rather than a translational neurotech company.
Mentioned in Market Notes
MOST RECENT COVERAGE
No items found.
Articles featuring
MaxWell Biosystems
No items found.